Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors

Objective. To develop three prognostic groups for disease specific mortality based on the binary classified pretreatment variables age, haemoglobin concentration (Hb), erythrocyte sedimentation rate (ESR), alkaline phosphatase (ALP), prostate-specific antigen (PSA), plasma testosterone and estradiol level in hormonally treated patients with metastatic prostate cancer (PCa). Material and methods. The present study comprised 200 Finnprostate 6 study patients, but data on all variables were not known for every patient. The patients were divided into three prognostic risk groups (Rgs) using the prognostically best set of pretreatment variables. The best set was found by backward stepwise selection and the effect of every excluded variable on the binary classification cut-off points of the remaining variables was checked and corrected when needed. Results. The best group of variables was ALP, PSA, ESR and age. All data were known in 142 patients. Patients were given one risk point each for ALP > 180 U/l (normal value 60–275 U/l), PSA > 35 µg/l, ESR > 80 mm/h and age < 60 years. Three risk groups were formed: Rg-a (0–1 risk points), Rg-b (2 risk points) and Rg-c (3–4 risk points). The risk of death from PCa increased statistically significantly with advancing prognostic group. Conclusion. Patients with metastatic PCa can be divided into three statistically significantly different prognostic risk groups for PCa-specific mortality by using the binary classified pretreatment variables ALP, PSA, ESR and age.

[1]  P. Klarskov,et al.  Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 , 2008, Scandinavian journal of urology and nephrology.

[2]  M. Ruutu,et al.  Ten‐year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy , 2007, The Prostate.

[3]  Masatoshi Watanabe,et al.  CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. , 2005, European urology.

[4]  I. Thompson,et al.  Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. , 2003, The Journal of urology.

[5]  T. D. de Reijke,et al.  Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. , 2002, European urology.

[6]  T. Tammela,et al.  PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer , 1999, European Urology.

[7]  J. Aro,et al.  Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer , 1999, The Prostate.

[8]  M. Ruutu,et al.  Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. , 1998, British journal of urology.

[9]  R. Sylvester,et al.  The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials , 1998, European Urology.

[10]  P. Ruff,et al.  Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. , 1997, American journal of clinical oncology.

[11]  H. Danielsen,et al.  Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. , 1997, The Journal of urology.

[12]  H. Grönberg,et al.  Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. , 1997, Urology.

[13]  C. Abbou,et al.  Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. , 1997, The Journal of urology.

[14]  A. Tewari,et al.  The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. , 1996, British journal of urology.

[15]  T. Peters,et al.  Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality. , 1995, British journal of urology.

[16]  L. Holmberg,et al.  Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population‐based consecutive cases , 1992, Cancer.

[17]  H. Yamanaka,et al.  Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis , 1992, Cancer.

[18]  L. Holmberg,et al.  Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. , 1991, The Journal of urology.

[19]  M. Terris,et al.  Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  G. Chodak,et al.  Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. , 1991, Urology.

[21]  N. Vogelzang,et al.  Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer , 1991 .

[22]  N. Vogelzang,et al.  INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGBE D2) PROSTATE CANCER , 1991 .

[23]  H. Yamanaka,et al.  The Significance of Erythrocyte Sedimentation Rate as a Prognostic Factor for Patients with Prostate Cancer: Gunma Urological Oncology Study Group Investigation , 1990, Japanese journal of cancer research : Gann.

[24]  H. Zincke,et al.  Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. , 1990, Mayo Clinic proceedings.

[25]  F. Debruyne,et al.  Analysis of prognostic factors in disseminated prostatic cancer. An update , 1990 .

[26]  P. Mulders,et al.  Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. , 1990, Cancer.

[27]  S. Ishikawa,et al.  Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. , 1989, The Journal of urology.

[28]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.

[29]  J. Hardy,et al.  Bone imaging and serum phosphatases in prostatic carcinoma. , 1985, British journal of urology.

[30]  H. Adlercreutz,et al.  Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. , 1981, Acta endocrinologica.

[31]  W. Ashburn,et al.  Nuclear bone imaging in metastatic cancer of the prostate , 1981, Cancer.

[32]  L. Theodorsen,et al.  Experiences with the Scandinavian recommended methods for determinations of enzymes in blood. A report by the Scandinavian Committee on Enzymes (SCE) , 1981, Scandinavian journal of clinical and laboratory investigation.

[33]  K. Kuoppasalmi Plasma testosterone and sex-hormone-binding globulin capacity in physical exercise. , 1980, Scandinavian journal of clinical and laboratory investigation.

[34]  D L Doxey,et al.  PRACTICAL HAEMATOLOGY , 1939, The Veterinary record.